https://www.selleckchem.com/pr....oducts/Pyroxamide(NS
013) and numbers of events experienced ( = 0.004). These effects were preserved 2 years after CS initiation. CS treatment may reduce the risk of suicide attempts and non-suicidal self-injury events in patients with a dual diagnosis of BD or SZD and ADHD. Based on our findings, clinicians should not withhold CS treatment from patients with concomitant ADHD for fear of deterioration of the underlying BD. However, to minimise the risk of manic episodes concomitant mood stabiliser treatment and close monitoring remains warra
Beğen
Yorum Yap
Paylaş
